Pseudomonas aeruginosa is emerging as a nososcomial pathogen. It has intrinsic as well as acquired resistance to many antimicrobial drugs. This study investigated the antimicrobial resistance pattern of P. aeruginosa from clinical isolates. It is a retrospective study carried out from June 2014 – December 2014 in Department of Microbiology at Al-Ameen Medical College, H&RC, Vijaypur. Out of 396 culture positive samples, 78 were identified as P. aeruginosa (by standard bacteriological identification procedures). These isolates were recovered from various specimens like pus, urine, sputum, broncho-alveolar lavage (BAL) and tracheal aspirate. Antimicrobial sensitivity testing was done by Kirby-Bauer disc diffusion method. Out of 396 cultures positive, 78 were positive for P. aeruginosa. The isolation rate was 19.69%. P. aeruginosa were more sensitive to combination drugs like piperacillin+tazobactum (93.5%) and cefoperazone+sulbactum (92.3%) followed by imipenem (88.2%), meropenem (87.1%). Sensitivity to amikacin, tobramycin, gentamicin and ceftazidime ranges from 35%-55%. Highest resistance rate was seen for amoxicillin followed by doxycycline. From our study, we concluded that P. aeruginosa is one of the most common nosocomial pathogen. It is sensitive to combination drugs like piperacillin+tazobactum and cefoperazone+sulbactum. It is also sensitive to carbapenems like imipenem, meropenem and aminoglycosides like amikacin, tobramycin, gentamicin, and cephalosporins like ceftazidime. Rational use of these drugs is necessary to prevent further spread of antimicrobial resistance among P. aeruginosa strains and also emergence of multi drug resistance.